Profiling pro-neural to mesenchymal transition identifies a lncRNA signature in glioma
Autor: | Xue Li, Peng Cheng, Wen Cheng, Chunmi Wei, Jianqi Wu, Gefei Guan, Qingyu Liang, Anhua Wu |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
ceRNA network lcsh:Medicine Biology Genome General Biochemistry Genetics and Molecular Biology 03 medical and health sciences lncRNA 0302 clinical medicine Glioma Gene expression medicine Humans Gene Proportional hazards model Competing endogenous RNA Research lcsh:R Mesenchymal stem cell PMT General Medicine Prognosis medicine.disease Phenotype Immune Gene Expression Regulation Neoplastic 030104 developmental biology 030220 oncology & carcinogenesis Cancer research RNA Long Noncoding Glioblastoma |
Zdroj: | Journal of Translational Medicine Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-16 (2020) |
ISSN: | 1479-5876 |
DOI: | 10.1186/s12967-020-02552-0 |
Popis: | Background Molecular classification has laid the framework for exploring glioma biology and treatment strategies. Pro-neural to mesenchymal transition (PMT) of glioma is known to be associated with aggressive phenotypes, unfavorable prognosis, and treatment resistance. Recent studies have highlighted that long non-coding RNAs (lncRNAs) are key mediators in cancer mesenchymal transition. However, the relationship between lncRNAs and PMT in glioma has not been systematically investigated. Methods Gene expression profiles from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), GSE16011, and Rembrandt with available clinical and genomic information were used for analyses. Bioinformatics methods such as weighted gene co-expression network analysis (WGCNA), gene set enrichment analysis (GSEA), Cox analysis, and least absolute shrinkage and selection operator (LASSO) analysis were performed. Results According to PMT scores, we confirmed that PMT status was positively associated with risky behaviors and poor prognosis in glioma. The 149 PMT-related lncRNAs were identified by WGCNA analysis, among which 10 (LINC01057, TP73-AS1, AP000695.4, LINC01503, CRNDE, OSMR-AS1, SNHG18, AC145343.2, RP11-25K21.6, RP11-38L15.2) with significant prognostic value were further screened to construct a PMT-related lncRNA risk signature, which could divide cases into two groups with distinct prognoses. Multivariate Cox regression analyses indicated that the signature was an independent prognostic factor for high-grade glioma. High-risk cases were more likely to be classified as the mesenchymal subtype, which confers enhanced immunosuppressive status by recruiting macrophages, neutrophils, and regulatory T cells. Moreover, six lncRNAs of the signature could act as competing endogenous RNAs to promote PMT in glioblastoma. Conclusions We profiled PMT status in glioma and established a PMT-related 10-lncRNA signature for glioma that could independently predict glioma survival and trigger PMT, which enhanced immunosuppression. |
Databáze: | OpenAIRE |
Externí odkaz: |